Acoramidis hydrochlorideProduct ingredient for Acoramidis
- Name
- Acoramidis hydrochloride
- Drug Entry
- Acoramidis
Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.4 Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis.1 Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.1
Acoramidis has been in development since at least 2013.2 It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.4,5
- Accession Number
- DBSALT003561
- Structure
Structure for Acoramidis hydrochloride (DBSALT003561)
- Synonyms
- Acoramidis HCl / Acoramidis hydrochloride
- External IDs
- AG-10 HCl / AG-10 hydrochloride / AG10 HCl / AG10 hydrochloride / ALXN-2060 HCl / ALXN-2060 hydrochloride / ALXN2060 HCl / ALXN2060 hydrochloride